The Future of CRISPR in Personalised Medicine

This comprehensive report delves into the transformative role of CRISPR technology in the field of personalised medicine. It provides an in-depth analysis of how CRISPR-Cas9 and associated gene-editing tools are revolutionising the development of therapies for genetic disorders, including sickle-cell disease and beta-thalassemia. Gain insights into the advantages and limitations of CRISPR compared to other gene-editing technologies, as well as the challenges that need to be addressed to enhance the clinical efficacy of CRISPR-based therapies.

The report also explores the impact of novel Cas proteins, base editing and prime editing technologies, alongside non-viral delivery platforms, in expanding the therapeutic potential of CRISPR. Additionally, it highlights future opportunities for in vivo and ex vivo CRISPR-based therapeutics to target a broader spectrum of diseases, offering valuable perspectives for pharmaceutical professionals navigating this rapidly evolving landscape.

Key Questions Answered:

• 1. How has CRISPR impacted the development of personalised medicines?
• 2. What are the advantages and disadvantages of CRISPR-Cas9 compared to other gene editing tools?
• 3. What challenges and obstacles need to be addressed to improve the clinical profile of CRISPR-based therapies?
• 4. How will novel Cas proteins, base editing and prime editing technologies impact the personalisation of CRISPR-based therapies?
• 5. What role do non-viral delivery platforms play in advancing CRISPR-based therapeutics?
• 6. What are the future opportunities for in vivo and ex vivo CRISPR-based therapeutics to target a broader array of diseases?

Key Companies:

Partial List of Participating Experts:

• Genome Engineer, Alia Therapeutics, Italy
• Senior Director, Head of Technology Development, Epicrispr Biotechnologies, US
• Chief Medical Officer, Arbor Biotechnologies, US
• Co-founder and CEO, SNIPR Biome, Denmark
• Chief Scientific Officer, Acuitas Therapeutics, Canada
• Chief Medical Officer, Arbor Biotechnologies, US
• President and CEO, Editas Medicine, US

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.